PRDS Pardes Biosciences, Inc.

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19. It applies reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19.

$1.09
As of 12/02/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  02/17/2021
Outstanding shares:  62,320,924
Average volume:  165,149
Market cap:   $64,190,552
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLGSZV0
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.25
PS ratio:   0.00
Return on equity:   -16.36%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy